In contrast, our real-world cohort, without strict eligibility restrictions, may capture risk emerging in specific subpopulations
[DOI] [PubMed] [Google Scholar] 312.Quintana-Cabrera R, Quirin C, Glytsou C, Corrado M, Urbani A, Pellattiero A, et al
This research was funded by the Inner Mongolia Autonomous Region Natural Science Foundation Project (2024LHMS08031)
Authorship All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the work as a whole, and have given their approval for this version to be published
The middle region of tirzepatide in GLP-1R was stabilized by the peptide-ECD-ECL1-ECL2 interface through both a polar network (T298 45.52b -S11 P -Y205 ECL1 -R299 ECL1 -D15 P -L32 ECD -S31 ECD -Q19 P ) and a complementary nonpolar network with ECD (L32, V36, W39 and Y88), ECL1 (W214), TM1 (L141 1.36b ) and TM2 (L201 2.71b ) via S11 P , Aib13 P , F22 P , W25 P and L26 P (Fig
Diabetes Obes Metab 22(8):12631277 Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al (2021) Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial